Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq:IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced a publication of Phase 1 clinical studies with risvodetinib (“risvo”), a potential disease-modifying therapy for Parkinson’s disease and related disorders. The publication entitled “A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease” was published online in the peer reviewed Journal of Parkinson’s Disease (DOI: 10.3233/JPD-230319) on January 13, 2024.
Related news for (IKT)
- Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
- Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
- inhibikase therapeutics announces closing of up to $275 million financing and advancement of ikt-001pro into a late stage clinical trial in pulmonary arterial hypertension
- inhibikase therapeutics announces pricing of $110 million private placement to advance ikt-001pro, an optimized prodrug of imatinib, into a late-stage trial in pulmonary arterial hypertension
- 24/7 Market News Snapshot 09 October, 2024 – Inhibikase Therapeutics, Inc. Common Stock (NASDAQ:IKT)